---
title: "Cevian Capital Lifts Smith & Nephew Stake Above 14% in Late-July Disclosure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293926975.md"
description: "Activist investor Cevian Capital increased its stake in Smith & Nephew to 14.01% as of July 22, 2026, crossing a UK disclosure threshold. The holding, comprising 117,912,733 shares, solidifies Cevian's position as a major shareholder, potentially influencing the medical device maker's governance and strategy. This development highlights sustained interest in shaping corporate performance within the competitive medtech market."
datetime: "2026-07-27T11:37:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293926975.md)
  - [en](https://longbridge.com/en/news/293926975.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293926975.md)
generator: "portal-rs"
---

# Cevian Capital Lifts Smith & Nephew Stake Above 14% in Late-July Disclosure

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

The latest announcement is out from Smith & Nephew Snats ( (SNN) ).

On July 27, 2026, Smith & Nephew filed a Form 6-K noting that activist investor Cevian Capital II GP Limited crossed a UK disclosure threshold in the company. The filing reports that on July 22, 2026, Cevian’s holdings rose from about 13.21% to 14.01% of Smith & Nephew’s voting rights, equivalent to 117,912,733 shares, all held via equity rather than derivatives.

The shares are legally registered in the name of Aurora Nominees Limited, acting on behalf of UBS AG as custodian, with Cevian Capital II Master Fund L.P. and a co-investment vehicle as the economic owners. The increase consolidates Cevian’s position as a major shareholder, potentially reinforcing its influence over governance and strategic direction at the medical device maker, a development likely to draw attention from other investors and regulators.

The notification was completed in Jersey and formally received by Smith & Nephew on July 24, 2026, in line with UK transparency requirements. While the filing does not outline any explicit strategic intentions, the growing stake underscores sustained interest from Cevian in shaping the company’s performance and corporate strategy in a competitive global medtech market.

The most recent analyst rating on (SNN) stock is a Hold  
 with a $30.00 price target.  
 To see the full list of analyst forecasts on Smith & Nephew Snats stock,  
 see the SNN Stock Forecast page. 

**Spark’s Take on SNN Stock**

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.

To see Spark’s full report on SNN stock,  
 click here. 

**More about Smith & Nephew Snats**

Smith & Nephew plc is a UK-based medical technology company, best known for its orthopaedics, sports medicine and wound management products. Listed in London with U.S. reporting obligations, it operates globally in the healthcare sector, supplying devices and therapies used by hospitals and clinics to treat musculoskeletal conditions and complex wounds.

The group’s shares, identified by ISIN GB0009223206, are widely held by institutional investors and traded on major exchanges. Its ownership structure and voting rights are subject to UK disclosure rules, making significant stake changes closely watched by markets and governance-focused stakeholders.

**Average Trading Volume:** 1,413,243

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $12.8B

### Related Stocks

- [SNN.US](https://longbridge.com/en/quote/SNN.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [Barclays Keeps Their Sell Rating on Smith & Nephew (SN)](https://longbridge.com/en/news/296468052.md)
- [Smith & Nephew CEO Deepak Nath’s restricted share vesting triggers GBP 513,423 share sale for taxes](https://longbridge.com/en/news/296215946.md)
- [Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics | SNN Stock News](https://longbridge.com/en/news/296188344.md)
- [REG - Smith & Nephew Plc Bank of America Corp - Holding(s) in Company](https://longbridge.com/en/news/296613344.md)
- [Smith & Nephew Reports Executive Share Award Vesting and Transactions](https://longbridge.com/en/news/295689090.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**